Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2018 | Telomere dysfunction to predict clinical outcomes in CLL

Chris Fegan, MB, MD, FRCP, FRCPath, from Cardiff University, Cardiff, UK, touches on several of the national and international cohort studies he has been involved in, proposing that telomere length is a prognostic factor in chronic lymphocytic leukemia (CLL). The studies have all identified the association between long telomere length and a better clinical outcome for patients. Moving forward, Dr Fegan suggests the use of telomere length to inform patients better on what is likely to happen to them, as it iss the only prognostic marker that is present at diagnosis This interview was recorded at the British Society for Hematology (BSH) 2018 Annual Scientific Meeting, Liverpool, UK.